The Chemopreventive Agent Development Research Group promotes and supports research on cancer preventive agent development, from preclinical studies to phase I clinical trials. The group’s projects aim to intercept the carcinogenic process by identifying and developing preventative agents with the potential to block, reverse, or delay the early stages of cancer. In addition, the group supports research on clinically translatable biomarkers that can be used to monitor tumor initiation and progression or assess efficacy of preventive interventions.
Cancer Prevention Clinical Trials Network (CP-CTNet)
Research Centers develop and conduct early phase clinical trials to assess the preventive potential of agents and interventions of varying classes.
PREVENT Cancer Preclinical Drug Development Program (PREVENT)
The peer-reviewed research pipeline supports new prevention interventions and biomarkers headed toward clinical trials.
Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)
Major medical research centers conduct systematic early clinical development of promising preventive agents.
DCP/PREVENT-funded Project Presentations at the 2022 AACR Annual Meeting
NCI will participate in the American Association for Cancer Research (AACR) Annual Meetings 2022, which will be held on April 8-13, 2022, including DCP/PREVENT-funded project presentations.
Vaccine to Prevent Hereditary Cancers Nears Human Trials
One of the first-ever vaccines for the prevention of colorectal and other cancers in patients at high genetic risk for these malignancies is expected to start its early phase safety and immunogenicity trial in the first quarter of 2022, according to investigators.